Natixis Advisors LLC Boosts Stock Position in Alkermes plc (NASDAQ:ALKS)

Natixis Advisors LLC increased its stake in Alkermes plc (NASDAQ:ALKS) by 190.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 36,490 shares of the company’s stock after purchasing an additional 23,921 shares during the quarter. Natixis Advisors LLC’s holdings in Alkermes were worth $1,021,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. V Square Quantitative Management LLC bought a new position in shares of Alkermes in the third quarter valued at approximately $29,000. Signaturefd LLC grew its position in Alkermes by 51.2% during the second quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock worth $34,000 after buying an additional 480 shares in the last quarter. Hexagon Capital Partners LLC increased its stake in Alkermes by 3,841.0% in the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock worth $37,000 after acquiring an additional 1,498 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Alkermes by 44.4% during the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock valued at $55,000 after acquiring an additional 703 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new position in shares of Alkermes in the second quarter worth approximately $116,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Insider Buying and Selling at Alkermes

In other news, EVP Craig C. Hopkinson sold 58,996 shares of Alkermes stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.08, for a total value of $1,774,599.68. Following the sale, the executive vice president now directly owns 83,300 shares in the company, valued at approximately $2,505,664. This trade represents a 41.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ALKS. Piper Sandler reissued an “overweight” rating and issued a $37.00 price target (down previously from $38.00) on shares of Alkermes in a report on Friday, October 25th. The Goldman Sachs Group lowered their price target on Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Mizuho upped their price objective on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Cantor Fitzgerald decreased their price objective on Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Finally, HC Wainwright restated a “neutral” rating and issued a $37.00 target price on shares of Alkermes in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.42.

Alkermes Stock Down 0.4 %

Shares of NASDAQ ALKS opened at $29.25 on Wednesday. The firm’s fifty day moving average is $27.95 and its 200 day moving average is $26.45. Alkermes plc has a 52 week low of $22.22 and a 52 week high of $32.88. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The company has a market cap of $4.73 billion, a price-to-earnings ratio of 15.00, a PEG ratio of 0.96 and a beta of 0.47.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.